AlphaRose Therapeutics Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 3

AlphaRose Therapeutics General Information

Description

Developer of gene therapy targeting a mutation of the HNRNPH2 gene, intended to make rare disease gene therapies accessible to all. The company develops personalized genetic medicine such as antisense oligonucleotide (ASO) therapy, a tailored treatment solution for a small population of patients, enabling children to have rare genetic disorders to have access to affordable genetic treatments.

Contact Information

Formerly Known As
Chrysalis Genetics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1401 Lavaca Street
  • Suite 851
  • Austin, TX 78701
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 1401 Lavaca Street
  • Suite 851
  • Austin, TX 78701
  • United States

AlphaRose Therapeutics Timeline

202420252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AlphaRose Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC Completed Generating Revenue
3. Equity Crowdfunding 28-Jul-2025 Completed Generating Revenue
2. Angel (individual) 26-Nov-2024 $2M $2.1M Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2024 $100K $100K Completed Startup
To view AlphaRose Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

AlphaRose Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AlphaRose Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Startup Warrior Accelerator/Incubator Minority
Advent Life Sciences Venture Capital Minority
Suncoast Ventures Venture Capital Minority
To view AlphaRose Therapeutics’s complete investors history, request access »

AlphaRose Therapeutics Acquisitions (1)

AlphaRose Therapeutics’s most recent deal was a Merger/Acquisition with Alpha Anomeric. The deal was made on 29-Apr-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Alpha Anomeric 29-Apr-2025 Merger/Acquisition Drug Discovery
To view AlphaRose Therapeutics’s complete acquisitions history, request access »

AlphaRose Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Alpha Anomeric Paris, France 2018

AlphaRose Therapeutics FAQs

  • When was AlphaRose Therapeutics founded?

    AlphaRose Therapeutics was founded in 2023.

  • Where is AlphaRose Therapeutics headquartered?

    AlphaRose Therapeutics is headquartered in Austin, TX.

  • What is the size of AlphaRose Therapeutics?

    AlphaRose Therapeutics has 7 total employees.

  • What industry is AlphaRose Therapeutics in?

    AlphaRose Therapeutics’s primary industry is Biotechnology.

  • Is AlphaRose Therapeutics a private or public company?

    AlphaRose Therapeutics is a Private company.

  • What is AlphaRose Therapeutics’s current revenue?

    The current revenue for AlphaRose Therapeutics is .

  • How much funding has AlphaRose Therapeutics raised over time?

    AlphaRose Therapeutics has raised $3.7M.

  • Who are AlphaRose Therapeutics’s investors?

    Startup Warrior, Advent Life Sciences, and Suncoast Ventures have invested in AlphaRose Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process